Orano Med and Orbit Discovery enter Collaboration to discover novel targeted radioligand therapies for cancer
Orano Med, a biotechnology company
developing Lead-212 (212Pb) Targeted Alpha Therapy against cancer, and Orbit
Discovery Ltd (Orbit), engaged in the discovery of therapeutic peptide hits, have
announced that they have entered into a collaboration to discover specific
Peptide Receptor Radionuclide Therapies against cancer cells and advance the
development of novel radiopharmaceuticals. Under the terms of the agreement,
Orbit will deploy its bead-based peptide display engine to discover peptide
leads specific to targets related to specific tumors.
To read more please visit:
Source: Orbit